Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

50.30 -0.92 (-1.80%)

Streaming Delayed Price Updated: 3:25 PM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

34 35 Next >

The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street ↗

December 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...

Via Benzinga

Novartis Launches New Share Buyback Program Of Up To $15B ↗

December 16, 2021

Novartis AG (NYSE: NVS) is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, adding it was confident in its top-line growth...

Via Benzinga

After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial ↗

December 15, 2021

Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would close the global Phase 3 MORNINGSKY trial. The decision comes after considering the changing COVID-19 landscape...

Via Benzinga

Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients ↗

December 14, 2021

Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 POLARIX study of Polivy (polatuzumab vedotin) with MabThera/Rituxan (rituximab) and the chemotherapy regimen...

Via Benzinga

Genentech’s Polivy Combination Reduced the Risk of Disease Worsening or Death by 27% in People With Previously Untreated Aggressive Form of Lymphoma

December 14, 2021

From Genentech

Via Business Wire

The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks ↗

December 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that...

Via Benzinga

Biotech Playbook 2021: No Help From Small Caps In Q4 ↗

December 14, 2021

Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but...

Via Talk Markets

Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings ↗

December 13, 2021

Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, posted a 60%...

Via Benzinga

Interim Data From Phase III HAVEN 6 Study Demonstrate Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A

December 13, 2021

From Genentech

Via Business Wire

The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More ↗

December 12, 2021

Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple...

Via Benzinga

Genentech Presents Pivotal Data at ASH 2021 for Novel Cancer Immunotherapy Mosunetuzumab

December 11, 2021

From Genentech

Via Business Wire

Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial ↗

December 10, 2021

Infinity Pharmaceuticals Inc (NASDAQ: INFI) presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS)....

Via Benzinga

Roche Posts Encouraging Follow-up Data From Tiragolumab/Tecentriq Trial In Lung Cancer ↗

December 10, 2021

Roche Holdings AG (OTC: RHHBY) reported follow-up efficacy, safety, and patient-reported outcomes data from the Phase 2 CITYSCAPE trial of tiragolumab plus...

Via Benzinga

New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech’s Novel Anti-TIGIT Tiragolumab Plus Tecentriq

December 10, 2021

From Genentech

Via Business Wire

Wednesday Global Investing Report ↗

December 08, 2021

Between the Amazon Cloud issues and the clouds gathering over the Ukraine border, it's getting harder to tell exactly what's happening to markets. Here are some insights into the international...

Via Talk Markets

7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts ↗

December 07, 2021

These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months.

Via InvestorPlace

Europe Approves Roche's Tocilizumab For Patients With Severe COVID-19 ↗

December 07, 2021

The European Commission has extended the marketing authorization for Roche Holdings AG's (OTC: RHHBY) Actemra/RoActemra (Tocilizumab) to treat patients with severe...

Via Benzinga

recession in 2022? ↗

December 06, 2021

China has cut its reserve requirement for lending by 50% giving a $188 bn boost to its market.

Via Talk Markets

Topics Economy

How Did Healthcare Stocks Perform Over This Volatile Month? ↗

December 06, 2021

It’s been a rough month for small-cap biotech stocks amidst a general correction in the market which brought general indices down about 10%.

Via Talk Markets

Immunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients ↗

December 06, 2021

Immunocore Holdings Plc (NASDAQ: IMCR) announced the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid...

Via Benzinga

Charms Of China ↗

December 03, 2021

Today the global stock market rout was pretty awful.

Via Talk Markets

Biden's New COVID-19 Plan Includes Reimbursement For Over The Counter, At-Home COVID Tests ↗

December 03, 2021

President Biden announced that private health insurance plans would soon reimburse people who buy over-the-counter (OTC), at-home rapid tests for COVID-19. What Happened...

Via Benzinga

Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact ↗

December 02, 2021

Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY...

Via Benzinga

52 Biggest Movers From Yesterday ↗

December 01, 2021

Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland...

Via Benzinga

35 Stocks Moving In Tuesday's Mid-Day Session ↗

November 30, 2021

Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares jumped 105.9% to $4.53. The FDA approved expanded labeling for Cumberland Pharmaceuticals’ Caldolor, an...

Via Benzinga

ImmunoGen Shares Rally After Ovarian Cancer Trial Meets Primary Endpoint Goal ↗

November 30, 2021

ImmunoGen Inc (NASDAQ: IMGN) shares have gained more than 30% during premarket trading in reaction to positive topline data from the SORAYA trial of mirvetuximab...

Via Benzinga

As FINRA's OTC Bulletin Board Closes Down, OTC Markets Group Becomes the Main Gateway Into the Regulated Over-the-Counter Market ↗

November 30, 2021

Photo by Marga Santoso on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch? ↗

November 28, 2021

The Swiss pharma needs to get its drug approved first.

Via The Motley Fool

How AI Is Reducing The Costly Toll Of Cancer Drug Development And Disrupting The BioPharma Space ↗

November 24, 2021

Bio-pharmaceutical investors know full well the drug discovery and development can be a long and uncertain process. Nowhere is that more true than in cancer drugs. This review looks at the history and...

Via Talk Markets

Topics Artificial Intelligence

Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders

November 23, 2021

From Genentech

Via Business Wire

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.